Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research, Immune Cell Function and Interaction, and CAR-T cell therapy research.
Co-expression of IL15 promotes effector differentiation and sustained proliferative capacity in ALPPL2-specific human CAR T cells.
Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer.
Secretogranin 2 binds LILRB4 resulting in immunosuppression.
177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors.
Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development.
An intranasally administered IgM protects against antigenically distinct subtypes of influenza A viruses.
Leptin as a key driver for organ fibrogenesis.
Acute kidney injury is associated with elevated urinary endotrophin.
Author Correction: Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
Supplementary Figure S6 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Supplementary Figure S3 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Figure S5 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Figure S4 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Supplementary Figure S5 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Figure S3 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Supplementary Figure S8 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Figure S2 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Supplementary Figure S4 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Supplementary Figure S7 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Data from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Supplementary Figure S9 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Figure S6 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Supplementary Table S2 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Supplementary Figure S1 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Supplementary Figure S10 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Data from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Supplementary Tables 1-5 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Figure S1 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Supplementary Figure S2 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
Supplementary Table S1 from <sup>177</sup>Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors